C. Pritchard

C. Pritchard, Jenna Khan, R. Martins, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes.

T. Walsh, M. King, C. Pritchard, 2018, American journal of human genetics.

Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer.

C. Pritchard, J. Mateo, Alejandro Athie, 2019, Advances in experimental medicine and biology.

Characterizing the Hypermutated Subtype of Advanced Prostate Cancer as a Predictive Biomarker for Precision Medicine

C. Pritchard, 2015 .

Genetic Testing for Prostate Cancer in Clinical Practice.

C. Pritchard, 2017, JCO precision oncology.

Discovery and reporting of clinically-relevant germline variants in advanced cancer patients assessed using whole-exome sequencing

M. Rubin, O. Elemento, A. Sboner, 2017, bioRxiv.

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies

P. Nelson, C. Pritchard, A. Alva, 2020, PloS one.

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer

J. Eshleman, N. Agarwal, E. Antonarakis, 2020, The oncologist.

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Anne E. Calvaresi, P. Carroll, A. M. López, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA Repair Pathway Alterations in Metastatic Castration‐resistant Prostate Cancer Responders to Radium‐223

C. Pritchard, E. Yu, E. Mostaghel, 2017, Clinical genitourinary cancer.

Systematic misclassification of missense variants in BRCA1 and BRCA2 “coldspots”

T. Walsh, M. King, T. Slavin, 2020, Genetics in Medicine.

Copy Number Variant Detection Using Next-Generation Sequencing

C. Pritchard, S. Salipante, A. Nord, 2015 .

A five‐CpG DNA methylation score to predict metastatic‐lethal outcomes in men treated with radical prostatectomy for localized prostate cancer

James Y. Dai, Jian-Bing Fan, J. Stanford, 2018, The Prostate.

Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome

K. Stefánsson, W. Frankel, S. Liyanarachchi, 2019, Journal of Medical Genetics.

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.

David Wu, C. Pritchard, C. Baik, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing.

Sheena M. Scroggins, C. Pritchard, S. Salipante, 2015, The Journal of molecular diagnostics : JMD.

Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.

E. Antonarakis, C. Pritchard, P. López-Casas, 2021, European journal of cancer.

Characterization of splice-altering mutations in inherited predisposition to cancer

T. Walsh, M. King, Ming K. Lee, 2019, Proceedings of the National Academy of Sciences.

CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.

A. Chinnaiyan, G. Ha, W. Oh, 2020, JCO precision oncology.

Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes

Michael P. Meers, S. Henikoff, G. Ha, 2022, bioRxiv.

DNA Yield From Tissue Samples in Surgical Pathology and Minimum Tissue Requirements for Molecular Testing.

C. Pritchard, J. Tait, M. Austin, 2016, Archives of pathology & laboratory medicine.

Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.

P. Goodfellow, W. Frankel, A. de la Chapelle, 2020, Gynecologic oncology.

Initiation of universal tumor screening for Lynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice

D. Bowen, G. Jarvik, A. Fichera, 2016, Cancer.

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

P. Nelson, Nola M. Klemfuss, C. Pritchard, 2020, JAMA oncology.

Germline, hematopoietic, mosaic, and somatic variation: interplay between inherited and acquired genetic alterations in disease assessment

C. Pritchard, E. Konnick, 2016, Genome Medicine.

PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer

W. Oh, A. Armstrong, T. Dorff, 2021, Prostate Cancer and Prostatic Diseases.

Microsatellite instability in prostate cancer by PCR or next-generation sequencing

P. Nelson, Nola M. Klemfuss, E. Antonarakis, 2018, Journal of Immunotherapy for Cancer.

Corrigendum: Classification and characterization of microsatellite instability across 18 cancer types

J. Shendure, Ronald J. Hause, C. Pritchard, 2017, Nature Medicine.

Inherited TP53 Variants and Risk of Prostate Cancer.

R. Nussbaum, E. V. Van Allen, K. Offit, 2021, European urology.

Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies.

C. Pritchard, B. Shirts, Heather H. Cheng, 2020, The Journal of the National Comprehensive Cancer Network.

The Prostate

J. Stanford, W. Isaacs, E. Davicioni, 2019 .

Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness.

C. Pritchard, 2019, The Canadian journal of urology.

New name for breast-cancer syndrome could help to save lives

C. Pritchard, 2019, Nature.

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer

P. Nelson, L. True, C. Higano, 2016, Asian journal of urology.

A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling

P. Nelson, Nola M. Klemfuss, C. Higano, 2016, The Prostate.

CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.

A. Chinnaiyan, G. Ha, W. Oh, 2020, JCO Precision Oncology.

Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.

Colin C Pritchard, Laura M Amendola, Gail P Jarvik, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.

Colin C Pritchard, Stephen J Salipante, Gail P Jarvik, 2012, The Journal of molecular diagnostics : JMD.

Postmortem Somatic Sequencing of Tumors From Patients With Suspected Lynch Syndrome Has Clinical Utility for Surviving Relatives.

C. Pritchard, J. Tait, P. Stanich, 2018, JCO precision oncology.

Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.

W. Frankel, J. Jónasson, C. Pritchard, 2018, Human pathology.

Characterization of a severe case of PIK3CA‐related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients

C. Pritchard, K. Tsuchiya, G. Mirzaa, 2018, American journal of medical genetics. Part A.

Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency

W. Frankel, C. Pritchard, H. Hampel, 2018, Modern Pathology.

Polyposis Caused by Low APC Mosaicism

H. Jacob, C. Pritchard, Y. Goldberg, 2016 .

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study

F. Gao, P. Goodfellow, L. Brinton, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference].

M. Rubin, D. Grignon, G. Kristiansen, 2021, Der Pathologe.

Integrative Clinical Genomics of Advanced Prostate Cancer

Lawrence D. True, Johann S. de Bono, Colin C. Pritchard, 2015, Cell.

BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.

C. Pritchard, F. Vakar‐Lopez, Heather H. Cheng, 2022, JCO precision oncology.

Ordering and Interpreting Precision Oncology Studies for Adults With Advanced Solid Tumors: A Primer.

C. Pritchard, B. Montgomery, M. Rettig, 2022, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.

P. Nelson, C. Pritchard, N. De Sarkar, 2021, JAMA oncology.

Biallelic Inactivation of BRCA 2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer

P. Nelson, C. Pritchard, Heather H. Cheng, 2016 .

The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer.

D. Juric, A. Zhu, J. Lennerz, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat.

R. Nussbaum, Y. Bombard, A. Wyatt, 2021, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.

M. Sydes, M. Gleave, R. Eeles, 2022, European urology.

A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing.

T. Walsh, M. King, S. Casadei, 2018, Blood.

Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia

T. Walsh, M. King, M. Churpek, 2016, Cancer.

Annotation error of a common β°‐thalassemia mutation (619 bp‐deletion) has implications for molecular diagnosis

C. Pritchard, J. Tait, M. Mikula, 2010, American journal of hematology.

Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels

E. Kroh, M. Tewari, M. Goodman, 2013, PloS one.

Molecular Genetics of Prostate Cancer and Role of Genomic Testing.

M. Rubin, F. Feng, C. Pritchard, 2022, Surgical pathology clinics.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

M. Rubin, A. Chinnaiyan, P. Nelson, 2018, The Journal of clinical investigation.

The utility of cerebrospinal fluid–derived cell-free DNA in molecular diagnostics for the PIK3CA-related megalencephaly-capillary malformation (MCAP) syndrome: a case report

I. Glass, C. Pritchard, G. Mirzaa, 2022, Cold Spring Harbor molecular case studies.

Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity

David A. Williams, T. Walsh, M. King, 2015, Haematologica.

Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance.

T. Walsh, M. King, I. Tomlinson, 2017, Gastroenterology.

Pathology and Diagnostic Pitfalls of Cholangiocarcinoma: Rising Incidence of an Old Cancer

C. Pritchard, M. Yeh, 2009 .

DNA Mismatch Repair Proteins and BRAF V600E Detection by Immunohistochemistry in Colorectal Cancer Demonstrates Concordance with Next Generation Sequencing

C. Pritchard, E. Konnick, L. A. Henricksen, 2022, Journal of Molecular Pathology.

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

M. Rubin, M. Sydes, M. Gleave, 2022, European urology.

PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution

Beth K. Martin, Martin, J. Shendure, 2016, JCI insight.

PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution

J. Shendure, Martin Kircher, K. Devriendt, 2016, JCI insight.

Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation

Jay Shendure, Colin C Pritchard, Stephen J Salipante, 2013, Genome research.

Genetic background influences murine prostate gene expression: implications for cancer phenotypes

P. Nelson, B. Mecham, C. Pritchard, 2007, Genome Biology.

Genomic correlates of clinical outcome in advanced prostate cancer

Yi Mi Wu, M. Loda, P. Kantoff, 2019, Proceedings of the National Academy of Sciences.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Thomas Wiegel, Colin C Pritchard, Stefano Fanti, 2018, European urology.

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

Ji-Ying Song, Egbert F. Smit, Arno Velds, 2016, Cell reports.

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Colin C. Pritchard, James L. Gulley, John M. Kirkwood, 2018, Journal of Immunotherapy for Cancer.

Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies.

J. Ioannidis, M. Tewari, V. Nair, 2014, American journal of epidemiology.

Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies

E. Kroh, M. Tewari, B. Wood, 2011, Cancer Prevention Research.

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer

E. V. Van Allen, G. Ha, C. Pritchard, 2021, JCI insight.

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

P. Nelson, Shunyou Wang, C. Pritchard, 2003, Cancer cell.

Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostate

P. Nelson, C. Ferguson, C. Pritchard, 2003, Genome Biology.

Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer

M. Rubin, D. Grignon, G. Kristiansen, 2020, The American journal of surgical pathology.

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.

Renato Martins, Colin C Pritchard, Stephen J Salipante, 2014, The Journal of molecular diagnostics : JMD.

The human (PEDB) and mouse (mPEDB) Prostate Expression Databases

Colin C. Pritchard, Peter S. Nelson, Nigel Clegg, 2002, Nucleic Acids Res..

Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer

B. Trock, W. Isaacs, J. Hicks, 2020, Clinical Cancer Research.

Intraductal carcinoma of the prostate in the absence of high‐grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations

J. Hicks, A. D. De Marzo, J. Epstein, 2019, The Journal of pathology.

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

Ming Yu, Colin C. Pritchard, Stephen J. Salipante, 2014, Nature Communications.

Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer

Benjamin J. Raphael, Matteo Pellegrini, Ming Yu, 2018, Systems Immuno-Oncology.

Deep sequencing with intronic capture enables identification of an APC exon 10 inversion in a patient with polyposis

T. Walsh, M. King, S. Casadei, 2014, Genetics in Medicine.

DNA Repair in Prostate Cancer: Biology and Clinical Implications.

Colin C Pritchard, Mark A Rubin, Christopher E Barbieri, 2017, European urology.

Conserved gene expression programs integrate mammalian prostate development and tumorigenesis.

Madhuchhanda Bhattacharjee, Robert A Sikes, P. Nelson, 2009, Cancer research.

Gene expression profiling in the developing prostate.

P. Nelson, C. Pritchard, 2008, Differentiation; research in biological diversity.

Alternative splicing of Pax3 produces a transcriptionally inactive protein.

C. Pritchard, G. Grosveld, A. Hollenbach, 2003, Gene.

Using the GEMM-ESC strategy to study gene function in mouse models

I. Huijbers, A. Berns, C. Pritchard, 2015, Nature Protocols.

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Michael D. Nyquist, P. Nelson, G. Ha, 2020, Cell reports.

The long tail of oncogenic drivers in prostate cancer

Yi Mi Wu, P. Kantoff, M. Rubin, 2018, Nature Genetics.

CD38 in Advanced Prostate Cancers

David C. Smith, Glenn C. Gaviola, M. Loda, 2021, European urology.

Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Michael D. Nyquist, P. Nelson, Jun Luo, 2019, The Journal of clinical investigation.

Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy.

W. Isaacs, E. Antonarakis, M. Carducci, 2019, JCO precision oncology.

DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant‐cell features

J. Epstein, C. Pritchard, T. Lotan, 2019, Histopathology.

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.

P. Nelson, A. Hsieh, L. True, 2019, JCO precision oncology.

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency

A. Chinnaiyan, N. Tunariu, C. Pritchard, 2019, European urology.

BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.

A. Sboner, H. Beltran, C. Pritchard, 2018, JCO precision oncology.

Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.

P. Nelson, C. Pritchard, S. Salipante, 2018, JCO precision oncology.

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study

M. Rubin, H. Beltran, C. Pritchard, 2018, European urology.

Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.

A. Ashworth, A. Wyatt, S. Tomlins, 2017, Cancer discovery.

MSH2 Loss in Primary Prostate Cancer

J. Eshleman, W. Isaacs, J. Hicks, 2017, Clinical Cancer Research.

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate

P. Nelson, L. True, M. Tretiakova, 2016, Oncotarget.

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

P. Nelson, C. Pritchard, B. Montgomery, 2016, European urology.

Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations

Colin C Pritchard, C. Pritchard, Maia Anderson, 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Resource Integrative Clinical Genomics of Advanced Prostate Cancer

David C. Smith, Glenn C. Gaviola, M. Loda, 2016 .

Integrative Clinical Genomics of Advanced Prostate Cancer Graphical

David C. Smith, Glenn C. Gaviola, M. Loda, 2015 .

Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2

A. Sigurdsson, K. Stefánsson, P. Sulem, 2017, Nature Communications.

Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing.

Ronald J. Hause, C. Pritchard, S. Salipante, 2018, Clinical chemistry.

Applying Ancestry and Sex Computation as a Quality Control Tool in Targeted Next-Generation Sequencing.

Colin C Pritchard, Stephen J Salipante, Brian H Shirts, 2016, American journal of clinical pathology.

Microsatellite instability detection by next generation sequencing.

Colin C Pritchard, Stephen J Salipante, Emily H Turner, 2014, Clinical chemistry.

The effects of genomic germline variant reclassification on clinical cancer care

T. Slavin, C. Pritchard, S. Gray, 2019, Oncotarget.

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

I. Huijbers, A. Berns, A. Schlicker, 2015, Proceedings of the National Academy of Sciences.

Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy

David A. Williams, T. Walsh, M. King, 2015, Nature Genetics.

Molecular Alterations and Biomarkers in Colorectal Cancer

C. Pritchard, W. Grady, 2014, Toxicologic pathology.

Colorectal cancer molecular biology moves into clinical practice

Colin C Pritchard, C. Pritchard, W. Grady, 2010, Gut.

IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS).

C. Pritchard, G. Grosveld, Fabrizio Picchione, 2011, Carcinogenesis.

Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells

I. Huijbers, A. Berns, M. Cozijnsen, 2014, EMBO molecular medicine.

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

P. Kantoff, M. Rubin, M. Sydes, 2020, European urology.

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

G. Mills, C. Paweletz, V. Velculescu, 2016, Clinical Cancer Research.

Detection of gene rearrangements in targeted clinical next-generation sequencing.

H. Abel, C. Pritchard, J. Pfeifer, 2014, The Journal of molecular diagnostics : JMD.

Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.

Robin L. Jones, C. Pritchard, G. Jour, 2014, Human pathology.

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland

Jos Jonkers, Hatice Yücel, I. Huijbers, 2016, Genes & development.

Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade

C. Pritchard, M. Schweizer, Laura S. Graham, 2021, Clinical Cancer Research.

A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer.

Chris P. Miller, D. Haussler, Su-In Lee, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Jumping translocations in myelodysplastic syndromes.

H. Deeg, David Wu, C. Pritchard, 2016, Cancer genetics.

Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance

P. Carroll, J. Brooks, J. McKenney, 2022, Cancer medicine.

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

E. Gallardo, P. Lapunzina, C. Pritchard, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of a precision oncology single molecule molecular inversion probe (smMIP) panel using a community-consensus approach

Malachi Griffith, Obi L. Griffith, Zachary L. Skidmore, 2018 .

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer

M. Dorschner, Janusz Dutkowski, B. Mecham, 2022, JCO precision oncology.

Reply to Hela Sassi, Olivier Caron, and Etienne Rouleau's Letter to the Editor re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50.

C. Pritchard, K. Maxwell, 2022, European urology.

Identification of community-consensus clinically relevant variants and development of single molecule molecular inversion probes using the CIViC database

Malachi Griffith, Obi L. Griffith, Erica K. Barnell, 2018 .

Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer

P. Goodfellow, W. Frankel, A. de la Chapelle, 2018, JAMA oncology.

Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations

G. Ha, L. True, M. Tretiakova, 2022, Cancer research communications.

The long tail of oncogenic drivers in prostate cancer

Yi Mi Wu, P. Kantoff, M. Rubin, 2018, Nature Genetics.

Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.

Sheena M. Scroggins, P. Goodfellow, A. de la Chapelle, 2016, Gastroenterology.

Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients

T. Walsh, M. King, J. Abkowitz, 2016, Haematologica.

Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.

W. Frankel, A. de la Chapelle, C. Pritchard, 2014, Gastroenterology.

Cis-Compound Mutations are Prevalent in Triple Negative Breast Cancer and Can Drive Tumor Progression

William Stafford Noble, W. L. Ruzzo, D. Haussler, 2016, bioRxiv.

Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations

C. Pritchard, S. Salipante, C. Lockwood, 2020, Practical laboratory medicine.

Glandular differentiation in dedifferentiated chondrosarcoma: molecular evidence of a rare phenomenon.

C. Pritchard, G. Jour, Yajuan J. Liu, 2015, Human pathology.

Germline heterozygous BLM mutations and prostate cancer risk.

W. Isaacs, E. Antonarakis, C. Pritchard, 2019, Journal of Clinical Oncology.

Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers

T. Walsh, M. King, O. Olopade, 2018, Clinical Cancer Research.

Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog.

Chang Liu, C. Pritchard, C. Vaughn, 2018, The Journal of molecular diagnostics : JMD.

Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford

C. Pritchard, T. Longacre, G. Fisher, 2020, JNCI cancer spectrum.

Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.

I. Chirivella, E. Antonarakis, C. Pritchard, 2023, European journal of cancer.

Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes

Malachi Griffith, Kilannin Krysiak, Erica K. Barnell, 2019, JCO clinical cancer informatics.

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas

C. Pritchard, James O. Park, E. Chiorean, 2022, The oncologist.

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Macie J. Rubin, M. Rubin, M. Sydes, 2023, European journal of cancer.

Werner syndrome through the lens of tissue and tumour genomics

Scott R. Kennedy, P. Welcsh, R. Monnat, 2016, Scientific Reports.

Mismatch Repair Protein Status of Non-Neoplastic Uterine and Intestinal Mucosa in Patients with Lynch Syndrome and Double Somatic Mismatch Repair Protein Mutations.

W. Frankel, C. Pritchard, P. Stanich, 2023, Human Pathology.

Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome

G. Jarvik, A. Burt, C. Pritchard, 2016, Journal of Genetic Counseling.

Improving performance of multigene panels for genomic analysis of cancer predisposition

Sheena M. Scroggins, T. Walsh, M. King, 2016, Genetics in Medicine.

Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey–Holden Prostate Cancer Academy Meeting

K. Pienta, J. Ippolito, J. Simons, 2017, The Prostate.

Prostate Cancer Screening in a New Era of Genetics.

P. Nelson, C. Pritchard, D. Lin, 2017, Clinical genitourinary cancer.

Isolation and characterization of the murine prostate short-chain dehydrogenase/reductase 1 (Psdr1) gene, a new member of the short-chain steroid dehydrogenase/reductase family.

P. Nelson, C. Ferguson, C. Pritchard, 2002, Gene.

Clinical, pathologic, and molecular features of amphicrine prostate cancer

C. Pritchard, M. Schweizer, E. Yu, 2023, The Prostate.

Circulating microRNAs and sudden cardiac arrest outcomes.

T. Rea, D. Siscovick, N. Sotoodehnia, 2016, Resuscitation.

LBA32PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC)

P. Lapunzina, C. Pritchard, M. Vidal, 2017 .

COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma

C. Pritchard, J. Tait, L. Joseph, 2010, BMC clinical pathology.

Comprehensive population-wide detection of Lynch syndrome in Iceland.

A. Sigurdsson, K. Stefánsson, P. Sulem, 2016 .

Lynch Syndrome: From Screening to Diagnosis to Treatment in the Era of Modern Molecular Oncology.

G. Jarvik, C. Pritchard, S. Cohen, 2019, Annual review of genomics and human genetics.

MLH1 Loss in Primary Prostate Cancer.

J. Eshleman, E. Antonarakis, C. Pritchard, 2023, JCO precision oncology.

Molecular testing of DNA damage response pathways in prostate cancer patients

C. Pritchard, Lalit R. Patel, Lalit R Patel, 2023, Current opinion in oncology.

Improved pregnancy and birth rates with routine application of nonsurgical embryo transfer

I. Huijbers, A. Berns, C. Pritchard, 2014, Transgenic Research.

EGFR mutations in squamous cell lung cancer in never-smokers.

C. Pritchard, L. Chow, C. Baik, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A mosaic PTEN mutation causing Cowden syndrome identified by deep sequencing

T. Walsh, C. Pritchard, R. Bennett, 2013, Genetics in Medicine.

Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.

E. Swisher, David Wu, C. Pritchard, 2018, JCO precision oncology.

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

M. Sydes, M. Gleave, R. Eeles, 2022, European Urology.

DNA-Repair Gene Mutations in Metastatic Prostate Cancer.

P. Nelson, K. Offit, C. Pritchard, 2016, The New England journal of medicine.

L11.05 RAPID VALIDATION OF CANCER GENES AND DRUG TARGETS IN GENETICALLY ENGINEERED MOUSE MODELS OF CANCER

I. Huijbers, A. Berns, M. Cozijnsen, 2013 .

Family-Specific Variants and the Limits of Human Genetics.

Colin C Pritchard, Brian H Shirts, Tom Walsh, 2016, Trends in molecular medicine.

Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.

C. Pritchard, E. Chiorean, V. Gadi, 2017 .

Management of Patients with Advanced Prostate Cancer

P. Kantoff, I. Tannock, M. Rubin, 2018 .

Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.

J. Ojemann, S. Saitta, C. Pritchard, 2022, Brain : a journal of neurology.

COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma

C. Pritchard, J. Tait, L. Joseph, 2010 .

Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies.

H. Beltran, C. Pritchard, T. Friedlander, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.